Business description: Alaunos Therapeutics, Inc.

Alaunos Therapeutics, Inc. is a biotechnology company. The Company's obesity and metabolic disorders program is advancing ALN1003, an oral small-molecule candidate being evaluated as a potential differentiated, non-hormonal, non-incretin approach for obesity- and metabolic-disease-relevant biology. ALN1003 is a preclinical, non-incretin, oral candidate targeting metabolic dysfunction beyond weight loss that may address insulin resistance, adipose signaling, liver biology, and body composition. ALN1003 is a preclinical, oral, non-hormonal metabolic therapeutic candidate being evaluated for: obesity-related metabolic dysfunction, MASH-relevant biology, and insulin resistance. The Company is advancing a pipeline of potentially transformative therapies for pulmonary hypertension and related cardiopulmonary diseases. The Company is developing ActRII-Fc ligand traps and complementary biologics. The Company's programs include VLR199, VLR247, VLR258, VLR360 and others.

Number of employees: 1

Sales by Activity: Alaunos Therapeutics, Inc.

Fiscal Period: December 2021 (USD) 2022 (USD) 2023 (USD) 2024 (USD) 2025 (USD)

Biotechnology

398K 2.92M 5K 10K 5K

Geographical breakdown of sales: Alaunos Therapeutics, Inc.

Fiscal Period: December 2021 (USD) 2022 (USD) 2023 (USD) 2024 (USD) 2025 (USD)

United States

398K 2.92M 5K 10K 5K

Executive Committee: Alaunos Therapeutics, Inc.

Manager TitleAgeSince
Chief Executive Officer 63 2025-07-01
Director of Finance/CFO 42 2025-02-21

Composition of the Board of Directors: Alaunos Therapeutics, Inc.

Director TitleAgeSince
Chairman 63 2023-09-21
Director/Board Member 40 2026-10-12

Shareholders: Alaunos Therapeutics, Inc.

NameStocks%Valuation
Fairmount Funds Management LLC
23.76 %
858,789 23.76 % 2 M $
3.952 %
142,878 3.952 % 278 612 $
2.377 %
85,914 2.377 % 167 532 $
Integrated Wealth Concepts LLC
1.383 %
50,000 1.383 % 97 500 $
1.357 %
49,047 1.357 % 95 642 $

Company details: Alaunos Therapeutics, Inc.

Alaunos Therapeutics, Inc.

501 East Las Olas Boulevard

33301, Fort Lauderdale

+

http://www.alaunos.com
address Alaunos Therapeutics, Inc.(TCRT)

Bio Therapeutic Drugs

Change 5-day change 1-year change 3-year change Capi.($)
+4.40%+1.84% - - 4.22M
-2.49%-3.76%+50.31%+62.10% 63.66B
-0.63%-2.91%+6.20%+89.22% 58.56B
-2.37%-2.22%+22.87%+82.31% 54.19B
-2.19%-6.15%+11.92%+108.08% 44.66B
-1.89%-7.28%+13.22%+19.74% 40.51B
-0.93%-0.47%+19.73%+43.75% 36.27B
+1.11%-6.44%+130.68%+641.83% 34.89B
-0.80%+0.61%+77.26%+56.26% 32.26B
-2.17%+16.65%-29.21%+474.05% 31.01B
Average -0.80%-0.91%+33.67%+175.26% 40B
Weighted average by Cap. -1.48%-1.85%+32.16%+150.90%
  1. Stock Market
  2. Stocks
  3. TCRT Stock
  4. Company Alaunos Therapeutics, Inc.